Immunological persistence in 4-6 and 7-9 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV/Hib

Human Vaccines

Volumn 6, Issue 2, 2010, Pages 189-193

  Zinke, Michael ^a   Disselhoff, Johann ^b   Gartner, Britta ^c,d   Jacquet, Jeanne Marie ^c,d  

^a GlaxoSmithKline Biologicals ^*  (Germany)

^b NONE

^c GLAXOSMITHKLINE   (Germany)

^d GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Antibody; Booster; Hepatitis B; Hexavalent vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE;

ARTICLE; BELGIUM; BLOOD SAMPLING; CHILD; DIPHTHERIA; FEMALE; FOLLOW UP; GERMANY; HAEMOPHILUS INFLUENZAE TYPE B; HEPATITIS B; HUMAN; IMMUNE RESPONSE; INFLUENZA B; MALE; PERTUSSIS; POLIOMYELITIS; PRESCHOOL CHILD; SCHOOL CHILD; TETANUS;

EID: 77953635928     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.2.10117     Document Type: Article

References (21)

1. Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt HJ, von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J 2006; 25:507-12.
2. Curran MP, Goa KL. DTPa-HBV-IPV/Hib vaccine (Infanrix hexa). Drugs 2003; 63:673-82.
3. Heininger U, DTP-HBV-IPV-059 Study Group; DTPHBV-IPV-096 Study Group, Sänger R, Jacquet JM, Schuerman L. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses. Vaccine 2007; 25:1055-63.
4. Omeñaca F, Garcia-Sicilia J, Boceta R, Sistiaga-Hernando A, García-Corbeira P. Antibody persistence and booster vaccination during the second and fifth years of life in a cohort of children who were born prematurely. Pediatr Infect Dis J 2007; 26:824-9.
5. Tichmann I, Preidel H, Grunert D, Habash S, Schult R, Maier R, et al. Comparison of the immunogenicity and reactogenicity of two commercially available hexavalent vaccines administered as a primary vaccination course at 2, 4 and 6 months of age. Vaccine 2005; 23:3272-9.
6. Tichmann-Schumann I, Soemantri P, Behre U, Disselhoff J, Mahler H, Maechler G, et al. Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2005; 24:70-7.
7. Tichmann I, Grunert D, Habash S, Preidel H, Schult R, Pfletschinger U, et al. Persistence of antibodies in children primed with two different hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type B vaccines and evaluation of booster vaccination. Hum Vaccin 2006; 2:249-54.
8. Zepp F, Knuf M, Heininger U, Jahn K, Collard A, Habermehl P, et al. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants. Vaccine 2004; 22:2226-33.
9. Saenger R, Maechler G, Potreck M, Zepp F, Knuf M, Habermehl P, Schuerman L. Booster vaccination with hexavalent DTPa-HBV-IPV/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV/Hib + HBV administered separately. Vaccine 2005; 23:1135-43.
10. Zinke M, Kappes R, Kindler K, Paulus-Koschik A, Goering U, Disselhoff J, et al. Immune memory to hepatitis B virus in 4-to-9-year old children vaccinated in infancy with four doses of hexavalent DTPa-HBVIPV/Hib vaccine. Hum Vaccin 2009; 5(9):592-8.
11. Recommended immunisation schedule for babies, children, adolescents and adults in Germany (source: German Standing Committee on Vaccination (STIKO): 7/2007). [accessed 2008]. Available at: http://www.rki.de/cln-049/nn-216436/EN/ Content/Prevention/Inf--Dis--Surveillance/ Vaccination/Immunisation--schedule. html.
12. Mallet E, Matisse N, Mathieu N, Langue J, Boisnard F, Soubeyrand B, et al. Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5-6-year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster. Vaccine 2004; 22:1415-22.
13. Carlsson RM, Claesson BA, Fagerlund E, Knutsson N, Lundin C. Antibody persistence in five-year-old children who received a pentavalent combination vaccine in infancy. Pediatr Infect Dis J 2002; 21:535-41.
14. Black S, Friedland LR, Ensor K, Weston WM, Howe B, Klein NP. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age. Pediatr Infect Dis J 2008; 27:341-6.
15. Guiso N, Njamkepo E, Vié le Sage F, Zepp F, Meyer CU, Abitbol V, et al. Long-term humoral and cellmediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life. Vaccine 2007; 25:1390-7.
16. Salmaso S. Sustained efficacy during the first 6 years of life of 3-component cellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics 2001; 108:E81.
17. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine 2003; 21:3542-9.
18. Granström M, Granström G. Serological correlates in whooping cough. Vaccine 1993; 11:445-8.
19. Torvaldsen S, McIntyre PB. Effect of the preschool pertussis booster on national notifications of disease in Australia. Pediatr Infect Dis J 2003; 22:956-9.
20. de Greeff SC, Mooi FR, Schellekens JF, de Melker HE. Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands. Pediatr Infect Dis J 2008; 27:218-23.
21. Kalies H, Grote V, Siedler A, Gröndahl B, Schmitt HJ, von Kries R. Effectiveness of hexavalent vaccines against invasive Haemophilus influenzae type b disease: Germany's experience after 5 years of licensure. Vaccine 2008; 26:2545-52.